High quality 3-Ethoxy-4 (ethoxycarbonyl)phenyl) Acetic Acid
CAS 99469-99-5
Product Introduction:
CAS No.
|
99469-99-5
|
Molecular Formula
|
C13H16O5
|
EINECS No
|
427-630-2
|
Purity
|
99%
|
Form
|
Powder
|
Pharmaceutical Intermediate
Repaglinide
For Diabetes
Product name
|
Repaglinide
|
Cas number
|
135062-02-1
|
Appearance
|
White powder
|
MF
|
C27H36N2O4
|
MW
|
452.58600
|
Repaglinide, a type of medicines for treating diabetes, is otropic agent which belongs to the non-sulfonylurea. It was developed by Boehringer Ingelheim from Germany, and won approval by FDA from the United States in December 1997. In 1998, it was successively listed in the United States and European countries, with commodity name as NovoNorm. Mainly used in the clinical treatment of type diabetes (non dependent) patients whose hyperglycemia can't be effectively controlled via diet, weight loss and exercise.
Repaglinide lowers blood glucose by stimulating the release the pancreas.
Repaglinide achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces secretion.
What is
Repaglinide
?
Repaglinide Hypoglycemic agents secretion is different in that the receptor by binding to different cell membranes to close β ATP- dependent potassium channel. It makes β cell depolarization, calcium channels open, so that inflow of calcium. This process induced β cells secrete .
Application &
Function of
Repaglinide
Repaglinide lowers blood glucose by stimulating the release of from the pancreas.
Repaglinide achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces secretion.